A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.

Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis

NCT00005571 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

NCT00417573 ·Status: COMPLETED ·Phase: PHASE2

Treatment With hOKT3gamma1(Ala-Ala) in T1DM

NCT00806572 ·Status: TERMINATED ·Phase: PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713 ·Status: RECRUITING ·Phase: PHASE1

Safety and Clinical Activity of Itolizumab in aGVHD

NCT05823675 ·Status: UNKNOWN ·Phase: PHASE1

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

NCT01147042 ·Status: TERMINATED ·Phase: PHASE4

A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis

NCT01140503 ·Status: TERMINATED ·Phase: NA

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

NCT06843408 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria

NCT07005713 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341 ·Status: COMPLETED ·Phase: PHASE3

Study of BHV-1400 in IgA Nephropathy

NCT07054684 ·Status: RECRUITING ·Phase: PHASE1

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

NCT01457430 ·Status: COMPLETED ·Phase: PHASE4

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805 ·Status: RECRUITING ·Phase: PHASE3

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

NCT01573533 ·Status: COMPLETED ·Phase: PHASE2

Immunological Effects From Intranasal Chitin Micro-Particles

NCT01508039 ·Status: COMPLETED ·Phase: NA

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

NCT02783482 ·Status: COMPLETED ·Phase: PHASE3

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome

NCT03560011 ·Status: SUSPENDED ·Phase: PHASE2/PHASE3

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

NCT00076726 ·Status: TERMINATED ·Phase: PHASE2

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

NCT03895801 ·Status: COMPLETED ·Phase: PHASE2

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147 ·Status: TERMINATED ·Phase: PHASE2

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

NCT00912093 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

NCT06994845 ·Status: RECRUITING ·Phase: PHASE3